Aug. 20 at 10:37 AM
$ABCL
The (so called) analysts have a consensus price target of
$14.62 for AbCellera Biologics
based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of
$30.0, and the most bearish reporting a price target of just
$7.0.
Result: Fair Value of
$14.63 (UNDERVALUED).
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-reports-phase-2-success-is-it-still
AbCellera has drawn renewed investor attention following encouraging PH 2 clinical data from one of its internal programs, alongside a substantial cash position. It is referenced to illustrate the scale, capabilities, and recent momentum of an established antibody-discovery platform, a much larger and better-capitalized company than MindWalk f.e., whose progress helps define the competitive landscape MindWalk operates within...
